Hyperfine Inc Net Assets
Hyperfine Inc net assets. Based on the latest financial reports, Hyperfine Inc (HYPR) has net assets worth $41.01 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($55.26 Million) and total liabilities ($14.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Hyperfine Inc (HYPR) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $41.01 Million |
| % of Total Assets | 74.2% |
| Annual Growth Rate | 6.08% |
| 5-Year Change | -77.98% |
| 10-Year Change | N/A |
| Growth Volatility | 88.98 |
Net Assets of Hyperfine Inc (2019–2025)
Net assets of Hyperfine Inc from 2019 to 2025. This chart illustrates how Hyperfine Inc's net assets have evolved over time, based on quarterly financial data. See Hyperfine Inc balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Hyperfine Inc (2019–2025)
The table below shows the annual net assets of Hyperfine Inc from 2019 to 2025. For live market cap and overall valuation, see market cap of Hyperfine Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $41.01 Million | -16.38% |
| 2024-12-31 | $49.04 Million | -41.90% |
| 2023-12-31 | $84.40 Million | -31.78% |
| 2022-12-31 | $123.72 Million | -33.56% |
| 2021-12-31 | $186.23 Million | +176.99% |
| 2020-12-31 | $67.23 Million | +133.59% |
| 2019-12-31 | $28.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hyperfine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 28197400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Hyperfine Inc Net Assets Breakdown (December 2025)
Hyperfine Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $10.00K | 0.02% |
| Other Components | $371.01 Million | 904.79% |
| Total Equity | $41.01 Million | 100.00% |
Hyperfine Inc Competitors by Market Cap
The table below lists competitors of Hyperfine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cingulate Inc
NASDAQ:CING
|
$57.82 Million |
|
iNtRON Biotechnology Inc
KQ:048530
|
$57.85 Million |
|
Inta Bina Group Bhd
KLSE:0192
|
$57.87 Million |
|
Young Heung I&
KO:012160
|
$57.89 Million |
|
ConvaTec Group PLC
LSE:CTEC
|
$57.78 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
$57.76 Million |
|
Thermaltake Technology Co Ltd
TWO:3540
|
$57.74 Million |
|
AmFIRST Real Estate Investment Trust
KLSE:5120
|
$57.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hyperfine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 49,040,000 to 41,005,000, a change of -8,035,000 (-16.4%).
- Net loss of 35,574,000 reduced equity.
- New share issuances of 27,009,000 increased equity.
- Other factors increased equity by 530,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-35.57 Million | -86.76% |
| Share Issuances | $27.01 Million | +65.87% |
| Other Changes | $530.00K | +1.29% |
| Total Change | $- | -16.38% |
Book Value vs Market Value Analysis
This analysis compares Hyperfine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.11x to 1.59x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $6.22 | $0.69 | x |
| 2020-12-31 | $2.67 | $0.69 | x |
| 2021-12-31 | $2.65 | $0.69 | x |
| 2022-12-31 | $1.76 | $0.69 | x |
| 2023-12-31 | $1.18 | $0.69 | x |
| 2024-12-31 | $0.68 | $0.69 | x |
| 2025-12-31 | $0.44 | $0.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hyperfine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -86.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -262.29%
- • Asset Turnover: 0.25x
- • Equity Multiplier: 1.35x
- Recent ROE (-86.76%) is below the historical average (-59.45%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -65.27% | 0.00% | 0.00x | 1.06x | $-21.66 Million |
| 2020 | -34.74% | -7944.56% | 0.00x | 1.06x | $-30.08 Million |
| 2021 | -34.81% | -4333.76% | 0.01x | 1.09x | $-83.46 Million |
| 2022 | -59.14% | -1073.73% | 0.05x | 1.08x | $-85.54 Million |
| 2023 | -52.42% | -401.00% | 0.12x | 1.12x | $-52.68 Million |
| 2024 | -83.03% | -315.90% | 0.22x | 1.20x | $-45.62 Million |
| 2025 | -86.76% | -262.29% | 0.25x | 1.35x | $-39.67 Million |
Industry Comparison
This section compares Hyperfine Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $296,528,539
- Average return on equity (ROE) among peers: -35.30%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hyperfine Inc (HYPR) | $41.01 Million | -65.27% | 0.35x | $57.79 Million |
| Abbott Laboratories (ABT) | $2.83 Billion | 34.08% | 0.96x | $190.23 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-95.88 Million | 0.00% | 0.00x | $2.34 Million |
| Aethlon Medical Inc (AEMD) | $-3.66 Million | 0.00% | 0.00x | $1.11 Million |
| Acutus Medical Inc (AFIB) | $-11.59 Million | 0.00% | 0.00x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $850.46 Million |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $2.43 Million |
| Allurion Technologies, Inc. (ALUR) | $-77.98 Million | 0.00% | 0.00x | $21.01K |
| Autonomix Medical, Inc. Common Stock (AMIX) | $5.89 Million | -283.55% | 0.29x | $1.61 Million |
| Artivion Inc (AORT) | $276.20 Million | -4.84% | 1.86x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $14.18 Million | 18.92% | 0.18x | $109.52 Million |
About Hyperfine Inc
Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners. The company also offers support and technical assistance services, as well as Hyperfine Image Viewer, a cloud picture arc… Read more